Table 3 Univariate analyses for DFS and OS of GC patients

Overall

1915

Sex

 Male

1333

Ref.

Ref.

 Female

582

0.93

0.77–1.11

0.400

0.87

0.72–1.06

0.161

Age (years)

 < 58

995

Ref.

Ref.

 ≥ 58

920

1.40

1.19–1.65

< 0.001

1.65

1.39–1.96

< 0.001

Tumor location

 GEJ + Upper 1/3

499

Ref.

Ref.

 Middle 1/3

468

0.82

0.66–1.01

0.063

0.81

0.65–1.00

0.053

 Lower 1/3

948

0.54

0.44–0.66

< 0.001

0.55

0.45–0.67

< 0.001

Tumor size

 < 3.2 cm

967

Ref.

Ref.

 ≥ 3.2 cm

948

2.93

2.45–3.51

< 0.001

3.05

2.53–3.68

< 0.001

Histologic grade

 Well-moderately

354

Ref.

Ref.

 Poorly

1516

1.62

1.27–2.06

< 0.001

1.51

1.19–1.92

< 0.001

T category

 T1

523

Ref.

Ref.

 T2

266

2.49

1.53–4.06

< 0.001

2.62

1.56–4.41

< 0.001

 T3

201

5.68

3.60–8.95

< 0.001

6.11

3.77–9.92

< 0.001

 T4a

889

11.93

8.18–17.38

< 0.001

13.05

8.71–19.56

< 0.001

 T4b

36

22.94

13.34–39.45

< 0.001

28.20

15.97–49.77

< 0.001

N category

 N0

806

Ref.

Ref.

 N1

344

2.49

1.81–3.43

< 0.001

2.68

1.94–3.71

< 0.001

 N2

330

5.23

3.95–6.94

< 0.001

5.08

3.79–6.82

< 0.001

 N3a

333

10.23

7.86–13.32

< 0.001

10.34

7.87–13.58

< 0.001

 N3b

102

16.90

12.30–23.22

< 0.001

18.88

13.61–26.20

< 0.001

VELIPI

 Negative

1050

Ref.

Ref.

 Positive

865

3.72

3.10–4.46

< 0.001

3.43

2.86–4.12

< 0.001

No. of retrieved LNs

 < 15

367

Ref.

Ref.

 ≥ 15

1548

1.22

0.98–1.51

0.078

1.17

0.93–1.45

0.175

Adjuvant treatment

 No

539

Ref.

Ref.

 Single drug

344

1.57

1.17–2.11

0.003

1.54

1.13–2.10

0.006

 Double drugs

688

2.13

1.66–2.71

< 0.001

2.27

1.76–2.92

< 0.001

 Triple drugs

210

3.24

2.44–4.31

< 0.001

2.98

2.21–4.02

< 0.001

    CRT

134

3.79

2.77–5.20

< 0.001

3.58

2.58–4.97

< 0.001

TD

 Absent

1714

Ref.

Ref.

 Present

201

4.14

3.42–5.02

< 0.001

4.45

3.66–5.42

< 0.001